Study Summary
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r/r AML/MDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.
Want to learn more about this trial?
Request More InfoInterventions
CYAD-02BIOLOGICAL
CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
ENDOXANDRUG
administered as preconditioning chemotherapy
FludaraDRUG
administered as preconditioning chemotherapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Mayo Clinic Cancer Center | Jacksonville | Florida | United States |
| University of Kansas Cancer Center | Fairway | Kansas | United States |
| Uz Leuven | Leuven | Belgium | |
| Chu Liege | Liège | Belgium | |
| AZ DELTA | Roeselare | Belgium |